| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/0961203302LU158OA |
| P8608 | Fatcat ID | release_vhtc6wcsbnh7pfrenwfpjaqwre |
| P698 | PubMed publication ID | 12004788 |
| P50 | author | Graciela S Alarcón | Q67485107 |
| John D Reveille | Q67485113 | ||
| P2093 | author name string | G McGwin | |
| B J Fessler | |||
| B A Baethge | |||
| H M Bastian | |||
| J M Roseman | |||
| A W Friedman | |||
| LUMINA Study Group. LUpus in MInority populations: NAture vs nurture | |||
| P2860 | cites work | Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans | Q24562483 |
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis | Q30449890 | ||
| Lupus erythematosus in the 1980s: a survey of 570 patients | Q33384712 | ||
| Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death | Q33403579 | ||
| The time-dependence of long-term prediction in lupus nephritis | Q33492379 | ||
| Environmental factors predicting nephritis in systemic lupus erythematosus | Q33565831 | ||
| Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus | Q35549094 | ||
| Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis) | Q35822079 | ||
| Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus | Q36361685 | ||
| Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique | Q38360359 | ||
| Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants | Q39563893 | ||
| Anti-dsdna and complement profiles as prognostic guides in systemic lupus erythematosus | Q40703151 | ||
| The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus | Q40974327 | ||
| Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study | Q41192552 | ||
| A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity | Q41615585 | ||
| Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group | Q43589680 | ||
| Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture | Q46430510 | ||
| Morbidity of systemic lupus erythematosus: role of race and socioeconomic status | Q46891297 | ||
| Disease activity and severity in patients with rheumatoid arthritis: relations to socioeconomic inequality | Q50144849 | ||
| Precipitating antibody to D.N.A. detected by two-stage electroimmunodiffusion. Study in S.L.E. and in rheumatoid arthritis. | Q53754153 | ||
| P433 | issue | 3 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| lupus erythematosus | Q188297 | ||
| lupus nephritis | Q1621830 | ||
| P304 | page(s) | 152-160 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis | |
| P478 | volume | 11 |
| Q35223839 | A retrospective analysis of clinical presentation of lupus nephritis |
| Q37208233 | Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients |
| Q33721381 | Admixture mapping of end stage kidney disease genetic susceptibility using estimated mutual information ancestry informative markers. |
| Q35953274 | African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV) |
| Q49523334 | Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis. |
| Q35552732 | Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis |
| Q94481800 | Application of principal component analysis and logistic regression model in lupus nephritis patients with clinical hypothyroidism |
| Q33871876 | Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus |
| Q33601679 | Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future |
| Q38631964 | B cells biology in systemic lupus erythematosus-from bench to bedside. |
| Q36012345 | Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation. |
| Q52620149 | CD11b Activity Modulates Pathogenesis of Lupus Nephritis. |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q36734776 | Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). |
| Q36663933 | Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). |
| Q36653353 | Chronic kidney disease in United States Hispanics: a growing public health problem. |
| Q49475768 | Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy |
| Q33421916 | Clinical and immunological characteristics in 552 systemic lupus erythematosus patients in a southern province of China |
| Q34146671 | Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. |
| Q36902869 | Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy |
| Q55264844 | Combined utilization of untimed single urine of MCP-1 and TWEAK as a potential indicator for proteinuria in lupus nephritis: A case-control study. |
| Q91803887 | Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan |
| Q35973816 | Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus |
| Q46319288 | Differences in the progression of primary progressive multiple sclerosis in Brazilians of African descent versus white Brazilian patients |
| Q37413878 | Disparities in lupus care and outcomes |
| Q37800294 | Do Asian patients have worse lupus? |
| Q31102783 | Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort |
| Q51173136 | Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients. |
| Q37212356 | Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis |
| Q37069392 | Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004 |
| Q36676984 | Ethnic and geographical differences in systemic lupus erythematosus: an overview |
| Q35216317 | Ethnic disparities in patients with systemic lupus erythematosus |
| Q43924407 | Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort |
| Q46496211 | Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes |
| Q43752384 | European ancestry decreases the risk of early onset, severe lupus nephritis in a single center, multiethnic pediatric lupus inception cohort |
| Q37398821 | European genetic ancestry is associated with a decreased risk of lupus nephritis |
| Q33821365 | Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation |
| Q33578262 | Geographical distribution, a risk factor for the incidence of lupus nephritis in China |
| Q34375769 | Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests |
| Q91393861 | HLA and kidney disease: from associations to mechanisms |
| Q54365434 | Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. |
| Q37434199 | Impact of immigration on the clinical expression of systemic lupus erythematosus: a comparative study of Hispanic patients residing in the USA and Mexico |
| Q50598390 | Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. |
| Q36540787 | Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry |
| Q35998043 | Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus |
| Q44894708 | Intravenous cyclophosphamide--resistant systemic lupus erythematosus in Arizona |
| Q46194883 | Kidney allograft survival of African American and Caucasian American recipients with lupus. |
| Q40246596 | Kidney transplantation for end-stage renal disease in lupus nephritis, a very safe procedure: a single Latin American transplant center experience |
| Q39789199 | Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis |
| Q53089425 | Long-term outcome in Japanese patients with lupus nephritis. |
| Q38362113 | Lupus in Latin-American patients: lessons from the GLADEL cohort. |
| Q95592748 | Lupus nephritis |
| Q37834473 | Lupus nephritis in Colombians: contrasts and comparisons with other populations |
| Q46720386 | Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes |
| Q47111503 | Lupus nephritis progression in FcγRIIB-/-yaa mice is associated with early development of glomerular electron dense deposits and loss of renal DNase I in severe disease |
| Q38162780 | Lupus nephritis: review of the literature |
| Q90577592 | Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers |
| Q46416350 | Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide |
| Q36191958 | Mapping by admixture linkage disequilibrium: advances, limitations and guidelines |
| Q46177271 | Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. |
| Q37423758 | Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma |
| Q30655475 | Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort |
| Q46665204 | Mortality and causes of death among incident cases of systemic lupus erythematosus in Finland 2000-2008. |
| Q38987696 | Multiple variants in 5q31.1 are associated with systemic lupus erythematosus susceptibility and subphenotypes in the Han Chinese population. |
| Q37290624 | Mycophenolate mofetil in the treatment of lupus nephritis. |
| Q51148648 | Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. |
| Q28301151 | Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus |
| Q36600357 | Outcome and predictors of kidney disease progression in Puerto Ricans with systemic lupus erythematosus initially presenting with mild renal involvement. |
| Q46592474 | Outcomes in African Americans and Hispanics with lupus nephritis. |
| Q44520690 | Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period |
| Q57329882 | Patients with familial and sporadic onset SLE have similar clinical profiles but vary profoundly by race |
| Q38035938 | Patients with lupus: an overview of culturally competent practice |
| Q36722180 | Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. |
| Q43654399 | Polymorphisms of the renin-angiotensin system genes in Brazilian patients with lupus nephropathy |
| Q33555419 | Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort |
| Q41622314 | Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort |
| Q47100353 | Predictors of incident proteinuria among patients with SLE. |
| Q37391150 | Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus |
| Q33455990 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort |
| Q37749647 | Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues |
| Q35890096 | Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis |
| Q35626485 | Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? |
| Q37146440 | Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy |
| Q33924437 | Recent clinical trials in lupus nephritis |
| Q57945954 | References |
| Q36697845 | Renal Biopsy: A much needed tool in patients with Systemic Lupus Erythematosis (SLE). |
| Q38649705 | Renal histology in Indigenous Australians with lupus nephritis. |
| Q37678723 | Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. |
| Q33497970 | Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution |
| Q35899141 | Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis |
| Q37023614 | Role of community and individual characteristics in physician visits for persons with systemic lupus erythematosus |
| Q41910493 | Serum alpha-actinin antibody status in systemic lupus erythematosus and its potential in the diagnosis of lupus nephritis |
| Q26746146 | Sex-specific effects of LiCl treatment on preservation of renal function and extended life-span in murine models of SLE: perspective on insights into the potential basis for survivorship in NZB/W female mice |
| Q36790796 | Sm antibodies increase risk of death in systemic lupus erythematosus |
| Q36112590 | Social Determinants of Health, the Chronic Care Model, and Systemic Lupus Erythematosus |
| Q49028552 | Socioeconomic status and organ damage in Mexican systemic lupus erythematosus women |
| Q36676990 | Socioeconomic status in systemic lupus erythematosus |
| Q37754835 | Systemic lupus erythematosus and ethnicity: nature versus nurture or nature and nurture? |
| Q40440734 | Systemic lupus erythematosus and infections: a retrospective study in Saudis |
| Q39053118 | Systemic lupus erythematosus biomarkers: the challenging quest |
| Q33363686 | Systemic lupus erythematosus in Pakistan |
| Q43728316 | Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: [corrected] contributions of admixture and socioeconomic status to renal involvement |
| Q44148062 | Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage |
| Q45099953 | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage |
| Q33379105 | Systemic lupus erythematosus in the Fars Province of Iran. |
| Q93193261 | Systemic lupus erythematosus: Diagnosis and clinical management |
| Q53649024 | Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. |
| Q88801489 | The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease |
| Q36198947 | The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry |
| Q33871748 | The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus |
| Q37137299 | Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort |
| Q28766942 | Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort |
| Q33632025 | US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). |
| Q36008840 | Understanding lupus nephritis: diagnosis, management, and treatment options |
| Q33621131 | Understanding the epidemiology and progression of systemic lupus erythematosus |
| Q39002132 | Update on Lupus Nephritis |
| Q92768947 | Update on lupus epidemiology: advancing health disparities research through the study of minority populations |
| Q37638666 | Urinary Albumin Levels are Independently Associated with Renal Lesion Severity in Patients with Lupus Nephritis and Little or No Proteinuria |
| Q38682220 | Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. |
| Q36203113 | Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. |
Search more.